Blockbuster diabetes drug earns heart indication
Blockbuster diabetes drug earns heart indicationA top-selling diabetes drug has gained a cardiovascular indication from FDA.
Major diabetes drug cuts heart attack riskNew data from Novo Nordisk will help its Victoza (liraglutide) for type 2 diabetes better compete against Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin). Victoza significantly reduced the combined incidence of heart attack, stroke and cardiovascular death in high-risk Type 2 diabetes patients, according to Novo Nordisk
[BLOG]: Obesity drug safety review
[BLOG]: Obesity drug safety reviewIn this blog post, Robert Kyle of AdverseEvents compares the results of a postmarket survey of 3 obesity drugs.
GLP-1 receptor more beneficial in reducing blood sugar compared to injectable therapy in Japanese patientsOnce-weekly dulaglutide is an effective treatment option for patients with type 2 diabetes who need to advance to injectable therapy, according to results from a Japanese study presented at the 2015 American Diabetes Association Scientific Sessions in Boston
FDA should pull diabetes drug ads, group saysConsumer advocacy group Public Citizen said this week that the Food and Drug Administration (FDA) must stop direct-to-consumer advertisements that market several “dangerous” diabetes medications for weight loss or blood pressure reduction.
FDA grants approval to Novo Nordisk chronic weight management drugFDA has approved the new drug application (NDA) for liraglutide [rDNA origin] injection (Saxenda, Novo Nordisk) , the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management.
Clinical study to research use of erectile dysfunction drug to treat vascular dementiaOn the 1-year anniversary of the first G8 summit on dementia, new funding has been announced for a study to research the use of tadalafil (Adcirca, Cialis; Eli Lilly), an erectile dysfunction drug, for the treatment of vascular dementia.
FDA drug approvals December 2014
FDA committee recommends approval for liraglutide as anti-obesity drugLiraglutide 3 mg (Saxenda, Novo Nordisk) has been recommended by an FDA Advisory Committee to be approved for use in the treatment of obesity
FDA panel backs liraglutide for obesityAn advisory committee to the FDA voted 14 to 1 to approve liraglutide for injection for chronic weight management in some obese patients.